Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 3/20 | 0.48 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.48 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | USP14 | P54578 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5746517 | 0.86 | L3MBTL1 (0.52) | TNFNOD1SMN1; SMN2LMNAREV1 | |
| SCHEMBL6349294 | 0.86 | MAPT (0.52) | TNFNOD1SMN1; SMN2LMNAREV1 | |
| SCHEMBL5773090 | 0.85 | HSD11B1 (0.53) | TNFNOD1SMN1; SMN2LMNAREV1 | |
| SCHEMBL5747352 | 0.84 | MAPK1 (0.55) | SMN1; SMN2LMNAPOLBMAPT | |
| SCHEMBL5798425 | 0.83 | THRB (0.56) | SMN1; SMN2LMNAREV1MAPTTHRB | |
| SCHEMBL5776077 | 0.82 | GFER (0.45) | SMN1; SMN2LMNAREV1RAB9AMAPT | |
| SCHEMBL5746692 | 0.81 | TNF (0.54) | TNFNOD1NOD2SMN1; SMN2LMNA | |
| SCHEMBL6348660 | 0.80 | LMNA (0.48) | LMNACNR1MAPT | |
| SCHEMBL5775668 | 0.78 | MAPT (0.53) | SMN1; SMN2LMNARAB9APOLBMAPT | |
| SCHEMBL5749721 | 0.78 | MAPT (0.53) | SMN1; SMN2LMNAGAARAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234046-A1 | Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders | KALYPSYS, INC. (US) | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234046-A1 | Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders | PPARA, PPARG, PPARD | TNF 4742/4885NOD1 2288/4885NOD2 3121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.